XNAS 08 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mr. Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 26.33 per share. | 02 Oct 2026 | 627 | 20,598 (0%) | 0% | 26.3 | 16,509 | - |
| Mr. Barry S. Ticho, M.D.,PhD | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.16 per share. | 01 Oct 2026 | 1,051 | 19,059 (0%) | 0% | 26.2 | 27,494 | - |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.06 per share. | 01 Sep 2026 | 1,600 | 20,110 (0%) | 0% | 31.1 | 49,691 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.51 per share. | 01 Sep 2026 | 3,945 | 21,710 (0%) | 0% | 30.5 | 120,370 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 26,250 | 0 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 26,250 | 137,124 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 14 Aug 2026 | 11,930 | 125,194 (0%) | 0% | 32.0 | 381,846 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 14 Aug 2026 | 637 | 124,557 (0%) | 0% | 32.5 | 20,682 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 10,000 | 30,422 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 10,000 | 0 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 14 Aug 2026 | 4,525 | 25,897 (0%) | 0% | 32.0 | 144,833 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 6,000 | 24,086 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 14 Aug 2026 | 242 | 25,655 (0%) | 0% | 32.5 | 7,857 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 32.01 per share. | 14 Aug 2026 | 2,716 | 21,370 (0%) | 0% | 32.0 | 86,932 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 14 Aug 2026 | 145 | 21,225 (0%) | 0% | 32.5 | 4,708 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2026 | 6,000 | 0 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.95 per share. | 03 Aug 2026 | 5,907 | 21,691 (0%) | 0% | 29.0 | 171,008 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.45 per share. | 03 Aug 2026 | 1,269 | 20,422 (0%) | 0% | 29.5 | 37,377 | Common Stock |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 29,555 | 29,555 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 29,555 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 17,786 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 29,747 | 29,747 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 29,747 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 7,639 | 7,639 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 7,639 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 19,441 | 19,441 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 19,441 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 21,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 11,650 | 11,650 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 11,650 | 0 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 14,777 | 14,777 | - | - | Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Jul 2026 | 14,777 | 0 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.62 per share. | 01 Jul 2026 | 6,728 | 28,098 (0%) | 0% | 32.6 | 219,434 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 33.27 per share. | 01 Jul 2026 | 500 | 27,598 (0%) | 0% | 33.3 | 16,634 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 29.95 per share. | 16 Jun 2026 | 1,457 | 18,086 (0%) | 0% | 29.9 | 43,637 | Common Stock |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 17,786 | 17,786 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.58 per share. | 01 Jun 2026 | 1,795 | 34,826 (0%) | 0% | 30.6 | 54,891 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.79 per share. | 01 May 2026 | 2,243 | 36,621 (0%) | 0% | 32.8 | 73,548 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.66 per share. | 01 Apr 2026 | 1,838 | 38,864 (0%) | 0% | 32.7 | 60,029 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 33.64 per share. | 20 Mar 2026 | 8,692 | 20,144 (0%) | 0% | 33.6 | 292,359 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 34.41 per share. | 20 Mar 2026 | 601 | 19,543 (0%) | 0% | 34.4 | 20,679 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.99 per share. | 17 Mar 2026 | 1,461 | 40,702 (0%) | 0% | 30.0 | 43,815 | Common Stock |
| Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 1,033 | 12,955 (0%) | 0% | 32.7 | 33,820 | Common Stock |
| Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 1,762 | 10,445 (0%) | 0% | 31.3 | 55,122 | Common Stock |
| Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 139 | 10,306 (0%) | 0% | 31.8 | 4,419 | Common Stock |
| Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 17 Mar 2026 | 30 | 10,276 (0%) | 0% | 32.9 | 986 | Common Stock |
| Jason Hoitt | Chief Patient Officer | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 748 | 12,207 (0%) | 0% | 33.4 | 24,965 | Common Stock |
| Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 172 | 10,209 (0%) | 0% | 31.8 | 5,468 | Common Stock |
| Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.84 per share. | 17 Mar 2026 | 37 | 10,172 (0%) | 0% | 32.8 | 1,215 | Common Stock |
| Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 1,274 | 13,476 (0%) | 0% | 32.7 | 41,710 | Common Stock |
| Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 922 | 12,554 (0%) | 0% | 33.4 | 30,772 | Common Stock |
| Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 2,173 | 10,381 (0%) | 0% | 31.3 | 67,980 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 483 | 40,901 (0%) | 0% | 31.8 | 15,354 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 6,100 | 41,384 (0%) | 0% | 31.3 | 190,831 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 2,587 | 47,484 (0%) | 0% | 33.4 | 86,342 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 3,577 | 50,071 (0%) | 0% | 32.7 | 117,109 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 17 Mar 2026 | 1,365 | 42,163 (0%) | 0% | 2.2 | 2,989 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 1,365 | 83,035 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.85 per share. | 17 Mar 2026 | 103 | 40,798 (0%) | 0% | 32.9 | 3,384 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 4,222 | 29,242 (0%) | 0% | 31.3 | 132,080 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 2,476 | 35,255 (0%) | 0% | 32.7 | 81,063 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 32.85 per share. | 17 Mar 2026 | 72 | 28,836 (0%) | 0% | 32.8 | 2,365 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 334 | 28,908 (0%) | 0% | 31.8 | 10,617 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 1,791 | 33,464 (0%) | 0% | 33.4 | 59,775 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 7,475 | 7,475 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 35,500 | 84,624 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 26,250 | 52,500 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 35,500 | 35,500 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 26,250 | 110,874 (0%) | 0% | 0 | Common Stock | |
| Jason Hoitt | Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| Jason Hoitt | Chief Patient Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 13,988 (0%) | 0% | 0 | Common Stock | |
| Thomas E. Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 14,750 | 14,750 (0%) | 0% | 0 | Common Stock | |
| Thomas E. Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,750 | 32,250 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 20,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 13,100 | 13,100 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,000 | 42,898 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 10,750 | 53,648 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 13,100 | 32,898 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 6,000 | 12,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 12,000 | 36,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 7,475 | 19,731 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 6,000 | 25,731 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 12,000 | 37,731 (0%) | 0% | 0 | Common Stock | |
| Arthur A. Levin | Director | Sale of securities on an exchange or to another person at price $ 36.80 per share. | 13 Mar 2026 | 605 | 4,237 (0%) | 0% | 36.8 | 22,264 | Common Stock |
| Arthur O. Tzianabos | Director, Interim Executive Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.33 per share. | 10 Mar 2026 | 3,955 | 35,694 (0%) | 0% | 8.3 | 32,945 | Common Stock |
| Arthur O. Tzianabos | Director, Interim Executive Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 3,955 | 118,696 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director, Interim Executive Chair | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Mar 2026 | 4,355 | 31,339 (0%) | 0% | 40.0 | 174,214 | Common Stock |
| Adrian R. Krainer | Director | Sale of securities on an exchange or to another person at price $ 39.74 per share. | 10 Mar 2026 | 33,243 | 283,302 (0%) | 0% | 39.7 | 1,320,964 | Common Stock |
| Adrian R. Krainer | Director | Sale of securities on an exchange or to another person at price $ 39.66 per share. | 02 Mar 2026 | 7,229 | 316,545 (0%) | 0% | 39.7 | 286,715 | Common Stock |
| Ian F. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 193,000 | 193,000 | - | - | Employee Stock Option (Right to Buy) | |
| Ian F. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 129,000 | 129,000 | - | - | Restricted Stock Units | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 53,000 | 53,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Jason Hoitt | Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 72,000 | 72,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jason Hoitt | Chief Patient Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 48,000 | 48,000 | - | - | Restricted Stock Units | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 1,211 | 4,842 (0%) | 0% | 0 | Common Stock | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 1,211 | 0 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.44 per share. | 08 Dec 2025 | 3,825 | 58,729 (0%) | 0% | 31.4 | 120,253 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 33.10 per share. | 08 Dec 2025 | 1,331 | 49,124 (0%) | 0% | 33.1 | 44,062 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 32.52 per share. | 08 Dec 2025 | 8,274 | 50,455 (0%) | 0% | 32.5 | 269,070 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 32.61 per share. | 08 Dec 2025 | 2,678 | 11,831 (0%) | 0% | 32.6 | 87,337 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.60 per share. | 08 Dec 2025 | 1,300 | 14,509 (0%) | 0% | 31.6 | 41,074 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 26,250 | 0 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 26,250 | 77,555 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.76 per share. | 03 Dec 2025 | 5,222 | 72,333 (0%) | 0% | 30.8 | 160,647 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.32 per share. | 03 Dec 2025 | 1,231 | 71,102 (0%) | 0% | 31.3 | 38,550 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 03 Dec 2025 | 6,367 | 64,735 (0%) | 0% | 31.3 | 199,481 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.15 per share. | 03 Dec 2025 | 1,681 | 63,054 (0%) | 0% | 31.1 | 52,358 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 31.85 per share. | 03 Dec 2025 | 500 | 62,554 (0%) | 0% | 31.8 | 15,923 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.35 per share. | 03 Dec 2025 | 1,989 | 19,798 (0%) | 0% | 31.3 | 62,346 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 10,000 | 0 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 03 Dec 2025 | 1,673 | 21,787 (0%) | 0% | 31.3 | 52,416 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 31.32 per share. | 03 Dec 2025 | 323 | 23,460 (0%) | 0% | 31.3 | 10,115 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.76 per share. | 03 Dec 2025 | 1,373 | 23,783 (0%) | 0% | 30.8 | 42,238 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 10,000 | 25,156 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 6,000 | 25,612 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 6,000 | 0 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.76 per share. | 03 Dec 2025 | 2,344 | 15,809 (0%) | 0% | 31.8 | 74,445 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.08 per share. | 03 Dec 2025 | 5,437 | 18,153 (0%) | 0% | 31.1 | 168,997 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 03 Dec 2025 | 1,004 | 23,590 (0%) | 0% | 31.3 | 31,456 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 31.31 per share. | 03 Dec 2025 | 194 | 24,594 (0%) | 0% | 31.3 | 6,075 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 30.76 per share. | 03 Dec 2025 | 824 | 24,788 (0%) | 0% | 30.8 | 25,349 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 4,317 | 0 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.85 per share. | 01 Dec 2025 | 651 | 51,305 (0%) | 0% | 30.8 | 20,082 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.34 per share. | 01 Dec 2025 | 419 | 51,956 (0%) | 0% | 30.3 | 12,712 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 4,317 | 53,441 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.14 per share. | 01 Dec 2025 | 405 | 52,375 (0%) | 0% | 30.1 | 12,207 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 29.56 per share. | 01 Dec 2025 | 661 | 52,780 (0%) | 0% | 29.6 | 19,540 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.14 per share. | 01 Dec 2025 | 762 | 17,170 (0%) | 0% | 30.1 | 22,968 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 11,981 | 19,176 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.85 per share. | 01 Dec 2025 | 1,225 | 15,156 (0%) | 0% | 30.8 | 37,788 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 11,981 | 0 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.34 per share. | 01 Dec 2025 | 789 | 16,381 (0%) | 0% | 30.3 | 23,937 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.56 per share. | 01 Dec 2025 | 1,244 | 17,932 (0%) | 0% | 29.6 | 36,775 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 30.34 per share. | 01 Dec 2025 | 898 | 21,006 (0%) | 0% | 30.3 | 27,244 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 12,357 | 0 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 30.85 per share. | 01 Dec 2025 | 1,394 | 19,612 (0%) | 0% | 30.8 | 43,002 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 30.14 per share. | 01 Dec 2025 | 868 | 21,904 (0%) | 0% | 30.1 | 26,163 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 29.56 per share. | 01 Dec 2025 | 1,416 | 22,772 (0%) | 0% | 29.6 | 41,860 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 12,357 | 24,188 (0%) | 0% | 0 | Common Stock | |
| Adrian R. Krainer | Director | Sale of securities on an exchange or to another person at price $ 29.72 per share. | 24 Nov 2025 | 40,472 | 323,774 (0%) | 0% | 29.7 | 1,202,719 | Common Stock |
| Adrian R. Krainer | Director | Sale of securities on an exchange or to another person at price $ 27.34 per share. | 14 Nov 2025 | 20,682 | 364,246 (1%) | 0% | 27.3 | 565,365 | Common Stock |
| Adrian R. Krainer | Director | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 14 Nov 2025 | 19,790 | 384,928 (1%) | 0% | 26.6 | 526,693 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.02 per share. | 03 Nov 2025 | 1,455 | 7,895 (0%) | 0% | 26.0 | 37,860 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.22 per share. | 03 Nov 2025 | 3,776 | 9,350 (0%) | 0% | 25.2 | 95,247 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.54 per share. | 03 Nov 2025 | 600 | 7,295 (0%) | 0% | 27.5 | 16,524 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 29.35 per share. | 03 Nov 2025 | 100 | 7,195 (0%) | 0% | 29.4 | 2,935 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2025 | 25,000 | 542,801 | - | - | Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Oct 2025 | 25,000 | 49,124 (0%) | 0% | 30 | 750,000 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 08 Oct 2025 | 25,000 | 74,124 (0%) | 0% | 0.6 | 15,000 | Common Stock |
| Ian F. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2025 | 380,000 | 380,000 | - | - | Restricted Stock Units | |
| Ian F. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2025 | 570,000 | 570,000 | - | - | Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Oct 2025 | 42,461 | 49,124 (0%) | 0% | 25.1 | 1,065,206 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.15 per share. | 03 Oct 2025 | 10,000 | 21,831 (0%) | 0% | 9.2 | 91,500 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 03 Oct 2025 | 10,000 | 11,831 (0%) | 0% | 25.1 | 250,650 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 10,000 | 34,800 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.64 per share. | 01 Oct 2025 | 5,343 | 13,126 (0%) | 0% | 23.6 | 126,316 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 1,211 | 1,211 | - | - | Restricted Stock Units | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 1,211 | 3,631 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 178,500 | 37,500 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 144,000 | 0 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.87 per share. | 02 Sep 2025 | 5,501 | 18,469 (0%) | 0% | 19.9 | 109,325 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Aug 2025 | 1,029 | 152,441 (0%) | 0% | 20 | 20,580 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 29 Aug 2025 | 45,996 | 91,585 (0%) | 0% | 20.1 | 925,858 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 29 Aug 2025 | 14,860 | 137,581 (0%) | 0% | 20.1 | 299,260 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 29 Aug 2025 | 6,345 | 11,831 (0%) | 0% | 20.1 | 127,317 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 29 Aug 2025 | 14,922 | 18,176 (0%) | 0% | 20.1 | 300,492 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 29 Aug 2025 | 9,150 | 33,098 (0%) | 0% | 7.1 | 64,691 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Aug 2025 | 850 | 23,948 (0%) | 0% | 20 | 17,000 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 29 Aug 2025 | 850 | 24,798 (0%) | 0% | 7.1 | 6,010 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 9,150 | 15,801 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 850 | 24,951 | - | - | Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 18.24 per share. | 18 Aug 2025 | 12,126 | 153,470 (0%) | 0% | 18.2 | 221,154 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.24 per share. | 18 Aug 2025 | 2,805 | 23,970 (0%) | 0% | 18.2 | 51,158 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 18.24 per share. | 18 Aug 2025 | 1,683 | 23,948 (0%) | 0% | 18.2 | 30,695 | Common Stock |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 26,250 | 165,596 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 10,000 | 26,775 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 10,000 | 10,000 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 20,000 | 20,000 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 6,000 | 6,000 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 12,000 | 12,000 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2025 | 6,000 | 25,631 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 13 Aug 2025 | 13,712 | 19,631 (0%) | 0% | 15 | 205,680 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.82 per share. | 01 Aug 2025 | 4,504 | 16,775 (0%) | 0% | 12.8 | 57,724 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.63 per share. | 01 Jul 2025 | 4,503 | 21,279 (0%) | 0% | 11.6 | 52,379 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 1,210 | 2,422 | - | - | Restricted Stock Units | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 1,210 | 2,420 (0%) | 0% | 0 | Common Stock | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | ||
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 02 Jun 2025 | 6,471 | 25,782 (0%) | 0% | 10.0 | 64,892 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 02 Jun 2025 | 1,745 | 32,253 (0%) | 0% | 10 | 17,450 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 May 2025 | 3,841 | 56,788 (0%) | 0% | 10 | 38,410 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 01 May 2025 | 22,790 | 33,998 (0%) | 0% | 10.0 | 228,543 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,210 | 3,632 | - | - | Restricted Stock Units | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,210 | 1,210 (0%) | 0% | 0 | Common Stock | |
| Ian F. Smith | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 238,420 | 238,420 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director, Interim Executive Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 122,651 | 122,651 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 89,000 | 89,000 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 4,842 | 4,842 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 8,907 | 139,346 (0%) | 0% | 8.3 | 73,661 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 10,382 | 148,253 (0%) | 0% | 8.7 | 90,012 | Common Stock |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 216,000 | 216,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 144,000 | 144,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 3,333 | 60,629 (0%) | 0% | 8.3 | 27,564 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 3,884 | 63,962 (0%) | 0% | 8.7 | 33,674 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 43,000 | 43,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 64,000 | 64,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 72,000 | 72,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 2,266 | 33,510 (0%) | 0% | 8.7 | 19,646 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 1,945 | 31,565 (0%) | 0% | 8.3 | 16,085 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 48,000 | 48,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 132,385 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 158,635 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 71,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 78,750 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 13,100 | 57,846 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 10,000 | 67,846 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 13,100 | 26,200 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 29,776 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 35,776 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 14,950 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 18,000 | - | - | Restricted Stock Units | |
| M. Kaye Edward | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 30 Dec 2024 | 35,000 | 96,885 (0%) | 0% | 0.6 | 21,000 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 35,000 | 567,801 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 6,786 | 61,885 (0%) | 0% | 13.0 | 88,158 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 2,586 | 44,746 (0%) | 0% | 13.0 | 33,596 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 1,552 | 21,476 (0%) | 0% | 13.0 | 20,164 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.69 per share. | 09 Dec 2024 | 12,114 | 23,028 (0%) | 0% | 13.7 | 165,814 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 6,170 | 68,671 (0%) | 0% | 12.8 | 78,837 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 13,945 | 47,332 (0%) | 0% | 12.8 | 178,182 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 9,696 | 35,142 (0%) | 0% | 12.8 | 123,891 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 74,841 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 20,000 | 20,000 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 10,000 | 10,000 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 10,000 | 61,277 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 44,838 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 6,000 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 12,000 | 12,000 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 4,317 | - | - | Restricted Stock Unit (RSU) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 48,591 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 48,792 | 11,981 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.07 per share. | 01 Dec 2024 | 10,000 | 51,277 (0%) | 0% | 12.1 | 120,698 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Dec 2024 | 10,000 | 61,277 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 48,792 | 51,277 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 38,838 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 12,357 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.68 per share. | 01 Nov 2024 | 10,000 | 2,485 (0%) | 0% | 12.7 | 126,803 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Nov 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Oct 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 10,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 01 Oct 2024 | 10,000 | 2,485 (0%) | 0% | 12.1 | 120,648 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 03 Sep 2024 | 9,400 | 3,085 (0%) | 0% | 14.9 | 140,236 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.41 per share. | 03 Sep 2024 | 600 | 2,485 (0%) | 0% | 15.4 | 9,245 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 03 Sep 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.58 per share. | 01 Aug 2024 | 10,000 | 2,485 (0%) | 0% | 14.6 | 145,843 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Aug 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Huw M. Nash | Chief Business Officer | 02 Jul 2024 | 2,467 | 33 (0%) | 0% | 13.1 | 32,320 | Common Stock | |
| Huw M. Nash | Chief Business Officer | 02 Jul 2024 | 33 | 0 (0%) | 0% | 13.9 | 459 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.75 per share. | 01 Jul 2024 | 10,000 | 2,485 (0%) | 0% | 13.7 | 137,458 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Jul 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 10,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | ||
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 03 Jun 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 03 Jun 2024 | 103 | 2,485 (0%) | 0% | 15.8 | 1,625 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.21 per share. | 03 Jun 2024 | 9,897 | 2,588 (0%) | 0% | 15.2 | 150,560 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 20 May 2024 | 2,664 | 27,000 (0%) | 0% | 16.0 | 42,746 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 20 May 2024 | 39,686 | 29,664 (0%) | 0% | 15.4 | 610,783 | Common Stock |
| Huw M. Nash | COO & CBO | 20 May 2024 | 50,000 | 0 (0%) | 0% | 15.4 | 769,500 | Common Stock | |
| Huw M. Nash | COO & CBO | 20 May 2024 | 50,000 | 46,000 | - | - | Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 20 May 2024 | 50,000 | 50,000 (0%) | 0% | 0.4 | 20,000 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 8,599 | 25,801 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 20 May 2024 | 8,599 | 2,598 (0%) | 0% | 15.0 | 129,327 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 20 May 2024 | 8,599 | 11,197 (0%) | 0% | 7.1 | 60,795 | Common Stock |
| Thomas Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 396,200 | 396,200 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 May 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 10,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.37 per share. | 01 May 2024 | 10,000 | 2,485 (0%) | 0% | 11.4 | 113,653 | Common Stock |
| Huw M. Nash | COO & CBO | 01 Apr 2024 | 50,000 | 96,000 | - | - | Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Apr 2024 | 400 | 0 (0%) | 0% | 13.6 | 5,444 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Apr 2024 | 60,929 | 400 (0%) | 0% | 13.2 | 805,768 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Apr 2024 | 50,000 | 61,329 (0%) | 0% | 0.4 | 20,000 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 01 Apr 2024 | 9,426 | 2,485 (0%) | 0% | 13.2 | 124,684 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Apr 2024 | 442 | 11,911 (0%) | 0% | 0.6 | 265 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 442 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.81 per share. | 28 Mar 2024 | 100 | 2,598 (0%) | 0% | 13.8 | 1,381 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 28 Mar 2024 | 5,026 | 2,698 (0%) | 0% | 13.2 | 66,287 | Common Stock |
| Stephen J. Tulipano | Former CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Stephen J. Tulipano | Former CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 159,000 | 159,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | ||
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 24,000 | 24,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 36,000 | 36,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 24,862 (0%) | 0% | 0 | Common Stock | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 4,116 | 20,746 (0%) | 0% | 6.1 | 25,102 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 11,150 | 69,350 (0%) | 0% | 6.1 | 67,999 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 80,500 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 106,500 | - | - | Restricted Stock Units | |
| Huw M. Nash | COO & CBO | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | ||
| Huw M. Nash | COO & CBO | 15 Mar 2024 | 13,100 | 15,445 (0%) | 0% | 0 | Common Stock | ||
| Huw M. Nash | COO & CBO | 15 Mar 2024 | 4,116 | 11,329 (0%) | 0% | 6.1 | 25,102 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 4,116 | 11,469 (0%) | 0% | 6.1 | 25,102 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 15,585 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 22,425 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 10,073 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 2,349 | 7,724 (0%) | 0% | 6.1 | 14,326 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 01 Mar 2024 | 10,000 | 2,485 (0%) | 0% | 7.7 | 77,469 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Mar 2024 | 5,504 | 12,485 (0%) | 0% | 0.6 | 3,302 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 5,504 | 80,442 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 31,739 | 0 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 13 Feb 2024 | 31,739 | 31,739 (0%) | 0% | 2.2 | 69,508 | Common Stock |
| S. Ticho Barry | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 01 Feb 2024 | 10,000 | 6,981 (0%) | 0% | 4.8 | 47,991 | Common Stock |
| S. Barry Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 02 Jan 2024 | 10,000 | 16,981 (0%) | 0% | 5.7 | 57,352 | Common Stock |
| Tulipano J. Stephen | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 107,400 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 121,100 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Kaye M. Edward | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 25,908 | 25,908 | - | - | Restricted Stock Unit (RSU) | |
| Allan Jonathan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tulipano Stephen J. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 60,773 | 60,773 | - | - | Restricted Stock Unit (RSU) | |
| Tulipano J. Stephen | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 60,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| S. Barry Ticho | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Nash Huw M. | COO & CBO | 01 Dec 2023 | 8,463 | 8,463 | - | - | Restricted Stock Unit (RSU) | ||
| Kaye M. Edward | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 200,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Allan Jonathan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 46,284 | 46,284 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 107,400 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Barry Ticho S. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 60,773 | 60,773 | - | - | Restricted Stock Unit (RSU) | |
| Huw M. Nash | COO & CBO | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | ||
| Stephen J. Tulipano | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Ticho S. Barry | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 60,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.60 per share. | 03 Jul 2023 | 15,000 | 25,895 (0%) | 0% | 10.6 | 158,973 | Common Stock |
| Jonathan Allan | General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 13.48 per share. | 21 Jun 2023 | 1,948 | 0 (0%) | 0% | 13.5 | 26,252 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | ||
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.13 per share. | 01 Jun 2023 | 15,000 | 40,895 (0%) | 0% | 11.1 | 166,964 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 04 May 2023 | 653 | 55,895 (0%) | 0% | 10 | 6,530 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 May 2023 | 5,513 | 81,245 (0%) | 0% | 10.0 | 55,134 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 01 May 2023 | 24,697 | 56,548 (0%) | 0% | 10.1 | 250,366 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 May 2023 | 24,967 | 86,758 (0%) | 0% | 10.0 | 249,767 | Common Stock |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unit (RSU) | |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 142,000 | 142,000 | - | - | Restricted Stock Unit (RSU) | |
| Huw M. Nash | COO & CBO | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unit (RSU) | ||
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unite (RSU) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 29,900 | 29,900 | - | - | Restricted Stock Unit (RSU) | |
| Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 44,800 | 44,800 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 03 Feb 2023 | 9,235 | 111,725 (0%) | 0% | 10.0 | 92,491 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 03 Feb 2023 | 3,763 | 120,960 (0%) | 0% | 10.0 | 37,745 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 31 Jan 2023 | 5,705 | 124,990 (0%) | 0% | 10.0 | 57,140 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 31 Jan 2023 | 267 | 124,723 (0%) | 0% | 10 | 2,670 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 31 Jan 2023 | 200 | 130,695 (0%) | 0% | 10 | 2,000 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | ||
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 02 Jun 2022 | 11,160 | 11,762 (0%) | 0% | 4.5 | 49,997 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 11,160 | 168,837 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 15,000 | 622,801 | - | - | Employee Stock Option (right to buy) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 25 May 2022 | 15,000 | 25,000 (0%) | 0% | 0.6 | 9,000 | Common Stock |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 308,000 | 308,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | ||
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | 03 Jan 2022 | 3,800 | 3,800 (0%) | 0% | 2.2 | 8,322 | Common Stock | |
| Huw M. Nash | COO & CBO | 03 Jan 2022 | 1,497 | 2,303 (0%) | 0% | 22.5 | 33,633 | Common Stock | |
| Huw M. Nash | COO & CBO | 03 Jan 2022 | 3,800 | 86,822 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 03 Jan 2022 | 200 | 0 (0%) | 0% | 24.1 | 4,814 | Common Stock | |
| Huw M. Nash | COO & CBO | 03 Jan 2022 | 2,103 | 200 (0%) | 0% | 23.4 | 49,219 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Oct 2021 | 5,700 | 102,022 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Oct 2021 | 5,700 | 0 (0%) | 0% | 24.8 | 141,506 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Oct 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Sep 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Sep 2021 | 5,700 | 107,722 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Sep 2021 | 5,700 | 0 (0%) | 0% | 26.0 | 148,223 | Common Stock | |
| Huw M. Nash | COO & CBO | 02 Aug 2021 | 5,700 | 0 (0%) | 0% | 28.9 | 164,554 | Common Stock | |
| Huw M. Nash | COO & CBO | 02 Aug 2021 | 5,700 | 113,422 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 02 Aug 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.55 per share. | 13 Jul 2021 | 3,300 | 130,895 (0%) | 0% | 33.6 | 110,726 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.68 per share. | 13 Jul 2021 | 39,866 | 134,195 (0%) | 0% | 32.7 | 1,302,929 | Common Stock |
| Huw M. Nash | COO & CBO | 01 Jul 2021 | 5,700 | 0 (0%) | 0% | 33.3 | 189,987 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Jul 2021 | 5,700 | 119,122 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Jul 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | ||
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | 01 Jun 2021 | 575 | 0 (0%) | 0% | 39.4 | 22,669 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Jun 2021 | 575 | 124,822 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Jun 2021 | 575 | 575 (0%) | 0% | 2.2 | 1,259 | Common Stock | |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 200,800 | 200,800 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | ||
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 1,842 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,776 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Sale of securities on an exchange or to another person at price $ 61.14 per share. | 01 Mar 2021 | 4,957 | 0 (0%) | 0% | 61.1 | 303,087 | Common Stock |
| Arthur A. Levin | Director | Sale of securities on an exchange or to another person at price $ 60.55 per share. | 01 Mar 2021 | 7,543 | 4,957 (0%) | 0% | 60.6 | 456,754 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Mar 2021 | 7,882 | 12,500 (0%) | 0% | 0.6 | 4,729 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 01 Mar 2021 | 2,776 | 2,776 (0%) | 0% | 0.4 | 1,110 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 01 Mar 2021 | 1,842 | 4,618 (0%) | 0% | 0.4 | 737 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 7,882 | 8,764 | - | - | Director Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 58.60 per share. | 22 Feb 2021 | 5,000 | 602 (0%) | 0% | 58.6 | 292,992 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 5,000 | 179,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 25,000 | 184,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 22 Feb 2021 | 5,000 | 5,602 (0%) | 0% | 4.5 | 22,400 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 22 Feb 2021 | 102 | 602 (0%) | 0% | 60 | 6,120 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 59.29 per share. | 22 Feb 2021 | 9,696 | 704 (0%) | 0% | 59.3 | 574,842 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 58.67 per share. | 22 Feb 2021 | 15,202 | 10,400 (0%) | 0% | 58.7 | 891,942 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 22 Feb 2021 | 25,000 | 25,602 (0%) | 0% | 4.5 | 112,000 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2021 | 10,000 | 13,447 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 60.67 per share. | 19 Feb 2021 | 10,000 | 0 (0%) | 0% | 60.7 | 606,652 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 19 Feb 2021 | 10,000 | 10,000 (0%) | 0% | 2.2 | 21,900 | Common Stock |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 32 | 0 (0%) | 0% | 57.1 | 1,828 | Common Stock | |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 200 | 32 (0%) | 0% | 60.5 | 12,102 | Common Stock | |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 1,800 | 232 (0%) | 0% | 59.8 | 107,724 | Common Stock | |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 1,500 | 4,232 (0%) | 0% | 57.7 | 86,494 | Common Stock | |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 2,200 | 2,032 (0%) | 0% | 59.0 | 129,837 | Common Stock | |
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 5,700 | 125,397 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 04 Jan 2021 | 5,700 | 5,732 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 21 Dec 2020 | 1,365 | 174,767 (0%) | 0% | 2.2 | 2,989 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 1,365 | 84,400 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.02 per share. | 21 Dec 2020 | 286 | 173,767 (0%) | 0% | 58.0 | 16,593 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 59.00 per share. | 21 Dec 2020 | 365 | 173,402 (0%) | 0% | 59.0 | 21,534 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.76 per share. | 21 Dec 2020 | 714 | 174,053 (0%) | 0% | 56.8 | 40,527 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 19,806 | 5,194 (0%) | 0% | 60 | 1,188,360 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 5,194 | 0 (0%) | 0% | 60 | 311,640 | Common Stock |
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 41,985 | 180,386 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 8,015 | 0 (0%) | 0% | 60 | 480,900 | Common Stock | |
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 8,015 | 8,015 (0%) | 0% | 0.6 | 4,809 | Common Stock | |
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 41,985 | 0 (0%) | 0% | 60 | 2,519,100 | Common Stock | |
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 41,985 | 41,985 (0%) | 0% | 0.6 | 25,191 | Common Stock | |
| Huw M. Nash | COO & CBO | 17 Dec 2020 | 8,015 | 172,371 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 5,700 | 131,097 | - | - | Employee Stock Option (Right to Buy) | ||
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 400 | 0 (0%) | 0% | 52.7 | 21,088 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 100 | 400 (0%) | 0% | 51.5 | 5,145 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 2,481 | 500 (0%) | 0% | 50.0 | 124,103 | Common Stock | |
| Huw M. Nash | COO & CBO | 01 Dec 2020 | 2,719 | 2,981 (0%) | 0% | 49.2 | 133,744 | Common Stock | |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 27 Nov 2020 | 12,152 | 25,000 (0%) | 0% | 50 | 607,600 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 25 Nov 2020 | 12,848 | 37,152 (0%) | 0% | 50 | 642,400 | Common Stock |
| Seth Harrison | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 39.00 per share. | 24 Nov 2020 | 375,000 | 17,161,713 (52%) | 1% | 39 | 14,625,000 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 47.61 per share. | 23 Nov 2020 | 210 | 0 (0%) | 0% | 47.6 | 9,998 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 46.85 per share. | 23 Nov 2020 | 5,294 | 210 (0%) | 0% | 46.8 | 248,009 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 20,000 | 23,447 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.08 per share. | 23 Nov 2020 | 4,300 | 15,700 (0%) | 0% | 45.1 | 193,838 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 23 Nov 2020 | 20,000 | 20,000 (0%) | 0% | 2.2 | 43,800 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.97 per share. | 23 Nov 2020 | 10,196 | 5,504 (0%) | 0% | 46.0 | 468,720 | Common Stock |
| Huw M. Nash | COO & CBO | 10 Nov 2020 | 50,000 | 0 (0%) | 0% | 45 | 2,250,000 | Common Stock |